Long-Acting Thymosin Alpha 1 Shows Promise for Cancer and Viral Infections

Thymosin α1 is a well-established immunomodulatory peptide, widely recognized for its ability to enhance immune responses and used in treating various conditions, including chronic hepatitis B and certain cancers. However, its naturally short half-life in the body often necessitates frequent dosing, which can limit its therapeutic efficacy and convenience for patients. This study specifically addresses the critical challenge of improving Thymosin α1's pharmacokinetic profile to create a more sustained, potent, and patient-friendly immunostimulant.

In vitro experiments definitively demonstrated that PASylated Thymosin α1 significantly enhanced the production of crucial immune signaling proteins, such as IFN-γ and IL-2, by T-cells, showing a remarkable 2.8-fold increase in cytokine levels compared to unmodified Thymosin α1 at equimolar concentrations (p<0.0001). A pivotal finding was the dramatic improvement in pharmacokinetic profile: the modified peptide exhibited a plasma half-life extending from approximately 2.5 hours for the native peptide to over 60 hours in plasma, representing an impressive 24-fold prolongation. In mouse models of viral infection, treatment with PASylated Thymosin α1 resulted in a profound 92% reduction in viral load compared to untreated controls (p<0.0001) and conferred a 55% greater survival rate than mice treated with native Thymosin α1, highlighting its superior protective capacity. Furthermore, in oncology models, PASylated Thymosin α1 effectively inhibited tumor growth by 65% compared to vehicle controls (p<0.005) and demonstrated a 38% stronger anti-tumor effect than daily native Thymosin α1 administration, underscoring its potential for sustained and potent immune activation against malignancies.